How to buy Provention Bio stock

Provention Bio, Inc is a biotechnology business based in the US. Provention Bio shares (PRVB) are listed on the NASDAQ and all prices are listed in US Dollars. Provention Bio employs 59 staff and has a market cap (total outstanding shares value) of 0.00.

Provention Bio share price

Use our graph to track the performance of PRVB stocks over time.

Provention Bio shares at a glance

• Key figures

Information last updated 2021-04-23.

52-week range	$7.54 - $19.19
50-day moving average	$10.67
200-day moving average	$13.92
Wall St. target price	$18.36
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-0.94

Buy Provention Bio shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Provention Bio stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Provention Bio, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Provention Bio financials

Gross profit TTM	$0
Return on assets TTM	-58.09%
Return on equity TTM	-102.04%
Profit margin	0%
Book value	$1.97
Market capitalisation	$501.4 million

TTM: trailing 12 months

Shorting Provention Bio shares

There are currently 3.8 million Provention Bio shares held short by investors – that's known as Provention Bio's "short interest". This figure is 35% up from 2.8 million last month.

There are a few different ways that this level of interest in shorting Provention Bio shares can be evaluated.

Provention Bio's "short interest ratio" (SIR)

Provention Bio's "short interest ratio" (SIR) is the quantity of Provention Bio shares currently shorted divided by the average quantity of Provention Bio shares traded daily (recently around 940198.27586207). Provention Bio's SIR currently stands at 4.06. In other words for every 100,000 Provention Bio shares traded daily on the market, roughly 4060 shares are currently held short.

However Provention Bio's short interest can also be evaluated against the total number of Provention Bio shares, or, against the total number of tradable Provention Bio shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Provention Bio's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Provention Bio shares in existence, roughly 60 shares are currently held short) or 0.0657% of the tradable shares (for every 100,000 tradable Provention Bio shares, roughly 66 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Provention Bio.

Find out more about how you can short Provention Bio stock.

Provention Bio share dividends

We're not expecting Provention Bio to pay a dividend over the next 12 months.

Provention Bio share price volatility

Over the last 12 months, Provention Bio's shares have ranged in value from as little as $7.54 up to $19.19. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Provention Bio's is 3.2487. This would suggest that Provention Bio's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Provention Bio overview

Provention Bio, Inc. , a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-6527, an oral CSF-1R inhibitor, which has completed Phase IIa clinical trial for the treatment of Crohn's disease; PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co. , Ltd. to develop and commercialize PRV-3279, a bispecific antibody-based molecule targeting the B cell surface proteins CD32B and CD79B in Greater China.

Frequently asked questions

• What percentage of Provention Bio is owned by insiders or institutions?

  Currently 19.839% of Provention Bio shares are held by insiders and 37.535% by institutions.

• How many people work for Provention Bio?

  Latest data suggests 59 work at Provention Bio.

• When does the fiscal year end for Provention Bio?

  Provention Bio's fiscal year ends in December.

• Where is Provention Bio based?

  Provention Bio's address is: 55 Broad Street, Red Bank, NJ, United States, 07701

• What is Provention Bio's ISIN number?

  Provention Bio's international securities identification number is: US74374N1028

• What is Provention Bio's CUSIP number?

  Provention Bio's Committee on Uniform Securities Identification Procedures number is: 74374N102